Recruiting NCT07551440
Identification of Therapeutic Targets in Metastatic Gastric Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Stomach Neoplasms, Benign. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Hong Kong
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Identification of Novel Therapeutic Targets in Gastric Cancer With Lymph Node or Distant Metastasis: An Explorative Study
Overview
This is a pilot study aiming at identifying novel therapeutic molecular targets in patients with gastric cancer with lymph nodes or distant metastasis. All patients who are diagnosed with gastric cancer with metastases in the Prince of Wales Hospital will be screened for eligibility.
Primary outcome measures
- Biobank construction [Time frame: Collect at baseline(pre-treatment) and/or during interval surgery if clinically indicated and/or after completing all systemic and surgical treatment if patient required an endoscopy or laparoscopy due to clinical need only.]
- Detection of noval therapeutic targets for treating gastric cancer cancer with metastases. [Time frame: Collect at baseline(pre-treatment) and/or during interval surgery if clinically indicated and/or after completing all systemic and surgical treatment if patient required an endoscopy or laparoscopy due to clinical need only.]
- Organoid culture for drug sensitivity assay [Time frame: Collect at baseline(pre-treatment) and/or during interval surgery if clinically indicated and/or after completing all systemic and surgical treatment if patient required an endoscopy or laparoscopy due to clinical need only.]
Secondary outcome measures (7)
- Clinical Outcome - Overall survival [Time frame: through study completion, an average of 5 year]
- Clinical Outcome - Progression-free survival [Time frame: through study completion, an average of 5 year]
- Clinical Outcome - Karnofsky Score [Time frame: At baseline measurement]
- Clinical Outcome - Time point of metastasis [Time frame: Recruitment till death or 5 year]
- Clinical Outcome - Number of previous chemotherapy/ target therapy/ immunotherapy [Time frame: Measured and asked at baseline]
- Clinical Outcome - Presence of ascites [Time frame: Recruitment till death or 5 year]
- Clinical Outcome - Cancer Restaging [Time frame: Post-treatment till death or 5 year]
Eligibility criteria
Inclusion criteria
- Patients age >= 18, <= 80 years old
- Performance status (WHO) <=2
- Gastric adenocarcinoma with lymph node metastasis or distant metastasis such as liver metastases, lung metastases, bone metastases, peritoneum metastases
- Patients with isolated ovarian metastasis could be included
- Patients who will be undergoing neoadjuvant chemotherapy/ target therapy/ immunotherapy or palliative chemotherapy/ target therapy/ immunotherapy
- Ability to give written consent before the commencement of treatment
Exclusion criteria
- Patient who will not be undergoing neoadjuvant chemotherapy/ target therapy/ immunotherapy or palliative chemotherapy/ target therapy/ immunotherapy
- Pregnancy or breastfeeding
- Patients with irreversible coagulation disorders
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Hong Kong · 1 center
- The Chinese University of Hong Kong — Hong Kong
Identifiers
NCT: NCT07551440 · 2023.117